Riyadh - Sharikat Mubasher: Apex Pharma, a leading Egyptian pharmaceutical company specializing in high-quality generic medications, launched operations at its first pharmaceutical plant in King Abdullah Economic City (KAEC), according to Chairman Magdy Elba.

The company is expected to begin distributing its products in the Kingdom after the Hajj season, with plans to produce 10 to 14 pharmaceuticals this year, Elba stated in an interview with Alarabiya Business.

He highlighted that the total investment allocated for the project’s first phase is estimated at SAR 300 million, noting that the company has invested SAR 180 million so far.

A few days ago, Apex Pharma launched Mavilor, the first Egyptian medicine for treating high blood pressure manufactured locally in its Saudi plant and approved by the Saudi Food and Drug Authority (SFDA). This milestone underscores the company’s commitment to the highest standards in the advanced pharmaceutical industry.

Elba further revealed that the company plans to invest EGP 3 billion by 2028 to expand its presence in the Egyptian market by adding more production lines and establishing a new pharmaceutical production facility.

In 2018, Apex Pharma signed an agreement with KAEC to establish a pharmaceutical plant in the Kingdom, strengthening the economic partnership between both countries.

The new plant spans a total area of 50,000 square meters and comprises ground and first floors, designed and to be constructed over two phases.

The first phase, covering 13,498 square meters, is dedicated to producing solid dosage forms. It includes commercial batch production areas, a pilot for process developments, a packaging zone, a warehouse, a laboratory area, office spaces, and training rooms.

Meanwhile, the second phase will be built on an area of 9,917 square meters for the complete production of different dosage forms.